bioXXmed AG bestätigt – Erstzulassung von DermaPro® in 2025 erwartet • news • onvista

EQS News: bioXXmed AG / Schlagwort(e): Sontiges

bioXXmed AG bestätigt – Erstzulassung von DermaPro® in 2025 erwartet

02.09.2024 / 17:00 CET/CEST

Inhaling the Mitteilung is the Issuer / Herausgeber responsible.

bioXXmed AG bestätigt – Erstzulassung von DermaPro® in 2025 erwartet

Darmstadt, September 2, 2024 – On 5.9.2024, the Bezugsfrist for the old Kapitalerhöhung began with a benevolent capital of EUR 2,014,000, which came into effect on 19.9.2024. The product was marketed for the further application of DermaPro® in the rancoderm GmbH – a 100% original version of bioXXmed AG – used. The focus is on the Fertigstellung der Regulatorische Onderlagen van DermaPro®, so that the implementation of an auditory production chain is carried out. The first Zulassung will take place in 2025. The instructions were carried out for the final completion of the procedure to approx. 3.7 million euros. benötigt. Only 14% of the costs of the DermaTools Biotech GmbH for Research and Development of DermaPro® have been invested in Mittel.

Proudly and with the resolution of the bankruptcy proceedings of DermaTools Biotech GmbH and the limited financing restrictions of the support of bioXXmed AG, further significant progress has been made in the preparation of the approval documentation. In February 2024, a plan was made for one of the bioXXmed AG state financiers, so the audit scheme, which was to be continued with the benefits of the war, could be continued. With the additional resources of the insolvency fund of the rancoderm GmbH since the same legal rights and the occupational health and safety requirements, including the compliance with the provisions of MDR (Medical Regulation), CE, ISO 13485 as well as FDA (Food & Drug Administration) to be acquired.

Separated for the international approval (certification) of a medical product is another implementation of quality guidelines, a risk management and the instrument an encompassing management assessment. The use of these resources in the daily work schedule will be separated by the self-understanding one of the companies. The rancoderm GmbH has acquired a product with DermaPro®, which changes in a high ethical and extremely complex situation. There are very high product qualities and a very good quality. Dem feels itself the rancoderm GmbH verbflichtet. The clinical analysis of DermaPro® works in patients with diabetes syndrome.

bioXXmed is now intensifying such a new partner for sales and new experiences, with, for example, cruris or decubitus.

About bioXXmed AG

bioXXmed AG is a Beteiligungsgesellschaft, which is an innovative company in Medizintechnik, Biotech or Pharma. Its current focus is on the treatment of long-term treatment bars. The effective product is DermaPro® for long-term treatment, treatment on the basis of diabetes. DermaPro® has its origins in the development for a Zulassung as a medical product in the USA and the EU. Innovation driver of DermaPro® is rancoderm GmbH. This company is bioXXmed 100% reliable.

Disclaimer

This Mitteilung may be worth ruling out. Solche zukunftsbezogeneen Aussagenspiegeln die Meinung von bioXXmed zum Datum dieser Mitteilung aufgrund bestimmter Annahmen and Erwartungen broader. The tactile health benefits and the organic health benefits can be experienced by the health care recipients. Since there is no change in the development of the best results, there is no accountability for updating or correcting.

Contact:

bioXXmed AG

Doctor Bruno Rosen

Butzbacherweg 6

64289 Darmstadt

Phone: +49-6151 951 581 2

Email address: [email protected]

02.09.2024 CET/CEST Release of a Corporate News/Finanznachricht, übermittelt durch EQS News – a service of EQS Group AG.

Inhaling the Mitteilung is the Issuer / Herausgeber responsible.

The EQS Distribution Services include notifications, Corporate News/Finanznachrichten and Press Releases.

Media archive under https://eqs-news.com

1979939 02.09.2024 Central European Time/Central European Time